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Millions of patients suffer from Alzheimer’s disease, and
intensive efforts to ﬁnd a cure for this devastating disorder
center on the proteases, which release the deadly amyloid
 
 
 
-peptide from its precursor. The cutting procedure is
thought to be cholesterol dependent and strategies to
lower cholesterol as therapeutic treatment are under
intensive investigation. Recent ﬁndings suggest that the
complete proteolytic machinery required for amyloid
 
 
 
-peptide generation is located within lipid rafts. Data by
Dotti and colleagues (Abad-Rodriguez et al., 2004), in
this issue, suggest that rafts isolate the cutting machinery
away from its deadly substrate. These ﬁndings describe a
novel mechanism for controlling proteolytic activity by
building a lipid boundary between proteases and their
substrates.
 
In all developed countries, humans live longer and longer.
Although we all wish to enjoy increased longevity, a longer life
is unfortunately associated with a dramatic increase for the risk
of Alzheimer’s disease (AD). This has been widely recognized
for years and numerous scientists have studied the cellular
mechanisms causing AD with the goal of finally identifying
targets for treatment. Indeed, it is likely that all genes directly
involved in the generation of the deadly amyloid 
 
 
 
-peptide
(A
 
 
 
), which forms the disease-defining amyloid plaques, have
now been identified (Haass, 2004). Currently, it is clear that A
 
 
 
is generated by proteolytic processing of 
 
 
 
-amyloid precursor
protein (APP), and two amyloidogenic secretases, 
 
 
 
- and
 
 
 
-secretase, are involved (Fig. 1). The 
 
 
 
-secretase, 
 
 
 
-site APP
cleaving enzyme (BACE), is a typical aspartyl protease.
 
 
 
-Secretase, however, is an unusual aspartyl protease complex
composed of four individual proteins (presenilin, nicastrin,
APH-1, and PEN-2), with presenilin carrying the protease
active site (Haass, 2004). 
 
 
 
-Secretase is uncommon not only in
its molecular composition but also in its proteolytic activity,
since it is able to cleave its substrate within the membrane (Fig.
1). A prerequisite of this intramembrane cut is the release of the
ectodomain of APP via cleavage by BACE or 
 
 
 
-secretase.
Removal of the ectodomain by BACE results in the production
of A
 
 
 
 following 
 
 
 
-secretase cleavage, whereas ectodomain
cleavage by 
 
 
 
-secretase is nonamyloidogenic since it cuts
within the A
 
 
 
 domain (Fig. 1).
Amyloidogenesis is known to be dependent on choles-
terol levels (Simons et al., 2001), and moreover, this seems to
have a direct relevance for AD, since high cholesterol is corre-
lated with an increased risk for the disease (Kuo et al., 1998).
In addition, the apolipoprotein 4 allele is known as a major
genetic risk factor for AD (Corder et al., 1993). At the cellular
level, A
 
 
 
 generation was found to occur in special cholesterol-
rich membrane subdomains called DRMs (detergent-resistant
membranes), and lowering cholesterol levels by treatment with
the cholesterol synthesis inhibitors, statins, resulted in a strong
decrease in A
 
 
 
 production (Simons et al., 1998; Fassbender et
al., 2001; Ehehalt et al., 2003). This is likely due in part to an
increase in nonamyloidogenic cleavage by 
 
 
 
-secretase (Kojro
et al., 2001). In animal models, statin treatment was also as-
sociated with a significant drop in A
 
 
 
 load (Fassbender et
al., 2001). Furthermore, a clear correlation between cholesteryl-
ester levels and A
 
 
 
 generation was reported in cultured cells
(Puglielli et al., 2001). More recently, it was demonstrated that
inhibition of the enzyme that regulates the conversion of free
cholesterol into cholesteryl-esters not only leads to a dramatic
lowering of AD pathology in animal models but is also associ-
ated with a reversion of cognitive deficits (Hutter-Paier et al.,
2004). Not surprisingly, efforts are under way to use cholesterol-
lowering drugs in patients to decrease A
 
 
 
 production. Indeed,
preliminary epidemiological studies and small clinical trials
suggest that lowering cholesterol levels may reduce the risk for
AD (Wolozin et al., 2000; Simons et al., 2002).
The strong cholesterol dependency of A
 
 
 
 generation
suggested that secretases might be located within DRMs and
this may regulate the processing of APP. Indeed, Ehehalt et
al. (2003) demonstrated that antibody cross-linking induced
BACE and APP to copatch within cholesterol-rich micro-
domains, and this resulted in increased A
 
 
 
 production. This
proposed localization of secretases is supported by the recent
findings of two different laboratories. Here, Abad-Rodriguez et
al. (2004) report that they were able to identify endogenous
BACE within DRMs of primary hippocampal neurons. Else-
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where, Vetrivel et al. (2004) recently demonstrated that the
completely assembled, biologically active 
 
 
 
-secretase com-
plex—consisting of the presenilin fragments APH-1, mature
Nicastrin, and PEN-2—resides within DRMs. Moreover, 
 
 
 
-sec-
retase was found in syntaxin 6–, syntaxin 13–, and VAMP4-
positive vesicles, demonstrating that 
 
 
 
-secretase accumulates
in the DRMs of late Golgi and endosomes (Vetrivel et al.,
2004), exactly where BACE is thought to be biologically active
(Haass et al., 1995; Vassar et al., 1999; Walter et al., 2001).
Similarly, monomeric and oligomeric A
 
 
 
 were concentrated in
DRMs in the brains of a mouse model for AD (Lee et al., 1998;
Kawarabayashi et al., 2004). Thus, it appears that the complete
A
 
 
 
 generating proteolytic machinery coexists within DRMs of
the same vesicles.
In this issue, the researchers provide a novel and unex-
pected explanation for why secretases are localized to choles-
terol rich membrane domains. They present data suggesting
that the DRM association of BACE restricts its access to APP,
which they demonstrate accumulates in detergent sensitive
membrane domains outside of DRMs (see Fig. 2). This may in-
dicate aberrant access of APP to DRMs, and hence aberrant A
 
 
 
production, during AD or it may indicate that even under phys-
iological conditions some APP molecules come into close con-
tact with DRMs. The latter seems more likely, since A
 
 
 
 is a
physiologically normal product and not produced just in the
brains of AD patients (Haass, 2004). These findings also dem-
onstrate a completely novel cellular mechanism for controlling
protease activity. Cells undergo major efforts to prevent pro-
teases from contacting proteins not destined to be digested.
This is accomplished by numerous mechanisms including syn-
thesis of inactive proforms to be activated at appropriate sites,
tagging protease substrates with ubiquitin, sequestering pro-
teases in membrane surrounded environments (endosomes/ly-
sosomes), or hiding the active sites of proteases within nar-
row tunnels (proteasomes). Abad-Rodrigues et al. (2004) and
Vetrivel et al. (2004) add yet another control mechanism. They
show that lipids can build an invisible boundary, corralling the
 
 
 
-secretase complex and BACE away from their substrate,
APP. Certainly, this mechanism did not evolve to protect us
from AD. So why do the secretases concentrate within DRMs?
A probable explanation is that 
 
 
 
-secretase is involved in sev-
eral signaling pathways including Notch signaling (Selkoe and
Kopan, 2003; Haass, 2004) and concentrating the proteolytic
machinery in small membrane domains facilitates these pro-
cesses. This would, however, imply that physiological sub-
strates such as Notch and others must gain access to DRMs, an
observation yet to be made.
There is, however, one obvious discrepancy between the
results of the current study and earlier ones that must be ad-
dressed. Abad-Rodrigues et al. (2004) demonstrate that, upon
moderate lowering of cholesterol, A
 
 
 
 generation surprisingly
increased, whereas a large body of previously published data
(see above) clearly demonstrated reduced A
 
 
 
 generation upon
cholesterol reduction. How could that be the case, and does that
mean that all previous approaches were simply wrong? The
truth may be found on both sides. The findings Dotti and col-
leagues (Abad-Rodrigues et al., 2004) are indeed in apparent
disagreement with studies showing that lowering cholesterol
Figure 1. Processing of APP by secretases.  -Secretase cleavage occurs within the A  domain and prevents amyloidogenesis. However, a small peptide
(p3) is generated by the subsequent cleavage of the C83 fragment by  -secretase. Besides p3, the large ectodomain (APPs- ) is secreted. A shorter APPs
species is secreted upon cleavage by BACE (APPs- ). The resulting C99 fragment is cleaved by  -secretase to produce A . The  -secretase cut releases the
APP intracellular domain (AICD), which may be involved in nuclear signaling. 
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inhibits amyloidogenesis, both in cultured cells and in animal
models (Simons et al., 1998; Fassbender et al., 2001; Ehehalt et
al., 2003). However, in these studies, cholesterol was always
strongly depleted and the cells that were used overexpressed
APP. In contrast, the current study investigated neurons, the
cells most affected by the deadly activity of A
 
 
 
. Moderate re-
duction of cholesterol led to increased A
 
 
 
 levels, whereas a
strong cholesterol reduction resulted in a significant drop in A
 
 
 
generation (Fig. 2), similar to that observed before (Simons et
al., 1998; Fassbender et al., 2001; Ehehalt et al., 2003). Thus,
the effects of cholesterol reduction are dose dependent, and two
apparently independent cellular mechanisms are affected. A
moderate reduction in cholesterol causes a disorganization of
DRMs, allowing more BACE to contact APP and resulting in
enhanced A
 
 
 
 generation (Fig. 2). A strong reduction in choles-
terol inhibits BACE/
 
 
 
-secretase activity and results in a dra-
matic drop in A
 
 
 
 generation, even though BACE and 
 
 
 
-secre-
tase can now contact APP directly (Fig. 2). In clear contrast to
this model, Ehehalt et al. reported that BACE cleavage of APP
occurs within lipid DRMs (Ehehalt et al., 2003), This discrep-
ancy might be due to the fact that when overexpressed a frac-
tion of APP may be mislocalized to DRMs, and then cleaved
by BACE, an observation also made by Abad-Rodrigues et al.
(2004). More work is needed to settle this controversy since the
effects of lowering brain cholesterol on the production of en-
dogenous A
 
 
 
 in mouse neurons or in human brains have not
been directly demonstrated. Although the current findings raise
some interesting questions, they do not necessarily challenge
cholesterol-lowering tactics as AD therapy/prevention since
animal studies to date are in clear favor of this strategy (Fass-
bender et al., 2001; Hutter-Paier et al., 2004). Moreover, cho-
lesterol lowering drugs are taken by numerous patients with
enormous beneficial effects on cardiovascular disorders and no
side effects concerning A
 
 
 
 generation or dementia have been
reported. Cholesterol-dependent processing of APP provides a
striking example how disease-based research can dramatically
Figure 2. A model describing the effects of cholesterol reduction on A  generation. For details, see text. 
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advance basic knowledge in cell biology, and vice versa. Who
would have thought, only 10 years ago, that DRMs might con-
tain and regulate the deadly machinery responsible for the most
abundant human neurodegenerative disorder and that this ma-
chinery might function via a novel and totally unexpected
mechanism of intramembrane proteolysis?
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